製薬・ヘルスケア部門（2021年年次報告）：M&Aと投資の動向

当レポートは、製薬部門におけるパートナーシップ、ライセンシング、M&A、資金調達を調査し（2021年）に製薬部門で登録されたパートナーシップやライセンス取引、M&A、株式/債券の募集、未公開株、ベンチャーファイナンスに関する詳細な情報を提供しています。また、過去6ヶ月間の取引件数と取引額に関する詳細な比較データを、取引タイプ、様々な治療分野、地域別に細分化して描いています。さらに、製薬部門の上位財務アドバイザリーファームに関する情報も掲載しています。

目次

第1章 目次

• 表のリスト
• 図のリスト

第2章 製薬およびヘルスケア、世界の、取引の概要

• 取引分析（2021年）
• タイプ別、取引数（2021年）
• タイプ別、取引額（2021年）
• 上位取引（2021年）
• 上位取引概要（2021年）

第3章 世界の製薬・ヘルスケア取引概要：タイプ別

• M＆A（2021年）
• エクイティオファリング取引（2021年）
• 債務オファリング取引（2021年）
• パートナーシップ取引（2021年）
• ライセンシング契約（2021年）
• プライベートエクイティ取引（2021年）
• ベンチャーキャピタル取引（2021年）

第4章 世界の製薬・ヘルスケア取引概要：市場別

• 腫瘍学（2021年）
• 中枢神経系（2021年）
• 感染症（2021年）
• 心臓血管（2021年）
• 免疫学（2021年）
• 代謝障害（2021年）
• 胃腸障害（2021年）

第5章 製薬・ヘルスケア取引概要：地域別

• 北米地域（2021年）
• 欧州地域（2021年）
• アジア太平洋地域（2021年）
• その他の地域（2021年）

第6章 世界の製薬・ヘルスケア上位ファイナンシャルアドバイザー

• 主要ファイナンシャルアドバイザー：M＆A（2021年）
• 主要ファイナンシャルアドバイザー：エクイティオファリング（2021年）

第7章 詳細情報

• 調査手法
• GlobalDataについて
• カスタマーサービス
• 開示情報
• 免責事項

List of Tables

List of Tables

• Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Table 2: Pharmaceuticals & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021
• Table 3: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (%), 2021
• Table 4: Pharmaceuticals & Healthcare, Top Deals, Global, 2021
• Table 5: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 7: Pharmaceuticals & Healthcare, Global, Top M&A Deals, 2021
• Table 8: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, 2021
• Table 9: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 10: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 11: Pharmaceuticals & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Table 12 Pharmaceuticals & Healthcare, Global, Top IPOs, 2021
• Table 13: Pharmaceuticals & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Table 14: Pharmaceuticals & Healthcare, Global, Top Secondary Offerings, 2021
• Table 15: Pharmaceuticals & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Table 16: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, 2021
• Table 17: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2021
• Table 18: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 19: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 20: Pharmaceuticals & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Table 21: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, 2021
• Table 22: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Table 23: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, 2021
• Table 24: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), 2021
• Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021
• Table 28: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), 2021
• Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2021
• Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2021
• Table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), 2021
• Table 32: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2021
• Table 33: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2021
• Table 34: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2021
• Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021
• Table 38: Pharmaceuticals & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2021
• Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), 2021
• Table 40: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2017 - Q4 2021
• Table 41: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (US$ m), 2021
• Table 42: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2021
• Table 43: Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2021
• Table 44: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2021
• Table 45: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 46: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 47: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, 2021
• Table 48: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2021
• Table 49: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 50: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 51: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2021
• Table 52: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2021
• Table 53: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, 2021
• Table 54: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2021
• Table 55: Pharmaceuticals & Healthcare, Top Venture Financing Deals, Global, 2021
• Table 56: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 57: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 58: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 59: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 60: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 61: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 62: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 63: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 64: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 65: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 66: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 67: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 68: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Table 69: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Table 70: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Table 71: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021
• Table 72: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Table 73: Pharmaceuticals & Healthcare, European Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021
• Table 74: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Table 75: Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021
• Table 76: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Table 77: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021
• Table 78: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2021
• Table 79: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2021

List of Figures

List of Figures

• Figure 1: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$ m), 2017- 2021
• Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021
• Figure 3: Pharmaceuticals & Healthcare, Global, Number of Deals (%), 2021
• Figure 4: Pharmaceuticals & Healthcare, Global, Deal Values (%), 2021
• Figure 5 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 6 Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 7: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2021
• Figure 8: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 10: Pharmaceuticals & Healthcare, Global, IPO Deals, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Figure 11: Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Figure 12: Pharmaceuticals & Healthcare, Global, PIPE Deals, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Figure 13: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021
• Figure 14: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 15: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 16: Pharmaceuticals & Healthcare, Global, Public Debt Offering Deals, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Figure 17: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Figure 18: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021
• Figure 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 20: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals Break down (%), 2021
• Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021
• Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), 2021
• Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2021
• Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2021
• Figure 26: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2021
• Figure 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2021
• Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2021
• Figure 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2021
• Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2021
• Figure 33: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number of Deals, 2021
• Figure 34: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), 2021
• Figure 35: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), 2021
• Figure 36: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 37: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 38: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2021
• Figure 39: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 40: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 41: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), 2021
• Figure 42: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), 2021
• Figure 43: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, 2021
• Figure 44: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2021
• Figure 45: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 46: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 47: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), 2021, 2017 - 2021
• Figure 48: Pharmaceuticals & Healthcare, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Figure 50: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021
• Figure 51: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 52: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 53: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 54: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 55: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 56: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 57: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2017 - 2021
• Figure 58: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2021-Q4 2021
• Figure 59: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Figure 60: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021
• Figure 61: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Figure 62: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021
• Figure 63: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Figure 64: Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021
• Figure 65: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), 2017 - 2021
• Figure 66: Pharmaceuticals & Healthcare, Rest of the World Deals, Number of Deals and Deal Value (US$ m), Q1 2021-Q4 2021

GlobalData's "Pharmaceutical and Healthcare Sector Mergers, Acquisitions and Investment Trend Annual Review - 2021" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in the year 2021. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharma Intelligence Center database and primary and secondary research.

Scope

• Analysis of the market trends for the pharmaceutical industry in the global arena.
• Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
• Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
• Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
• Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
• Analysis of partnership and licensing deals based on clinical stage of development of products.
• Summary of the pharmaceutical deals globally in the six months.
• Information on the top deals happened in the pharmaceutical industry.
• Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
• League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

• Enhance your decision making capability in a more rapid and time sensitive manner.
• Find out the major deal performing segments for investments in your industry.
• Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
• Identify companies that are aggressively looking to raise capital in the market
• Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
• Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
• Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
• Identify growth segments and opportunities in each region within the industry.
• Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Pharmaceutical & Healthcare, Global, Deals Summary

• 2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2021
• 2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2021
• 2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2021
• 2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2021
• 2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2021

3 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type

• 3.1 Pharmaceuticals & Healthcare, Global, M&A, 2021
• 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2021
• 3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2021
• 3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2021
• 3.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2021
• 3.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2021
• 3.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2021

4 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market

• 4.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2021
• 4.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2021
• 4.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2021
• 4.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2021
• 4.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2021
• 4.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2021
• 4.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2021

5 Pharmaceuticals & Healthcare, Deal Summary, By Geography

• 5.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2021
• 5.2 Pharmaceuticals & Healthcare, European Region Deals, 2021
• 5.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2021
• 5.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2021

6 Pharmaceuticals & Healthcare, Global, Top Financial Advisors

• 6.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2021
• 6.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2021

7 Further Information

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us
• 7.4 Disclosure information
• 7.5 Disclaimer